During 2005 and 2006, Acta Radiologica has published several articles on vertebroplasty and kyphoplasty in vertebral compression fractures due to osteoporosis or tumor infiltration. In this issue, we have two articles by PFLUGMACHER et al. (4, 5) , describing 1-and 2-year follow-up of vertebroplasty and kyphoplasty, respectively.
The technical description of vertebroplasty has been described in detail by GUGLIELMI et al. (1) , and kyphoplasty by PFLUGMACHER et al. (3) . Both methods are highly effective in the immediate relief of pain. During the follow-up of patients with osteoporosis there is some increase in pain and the improvement in kyphosis angulation decreases. The height of the vertebral bodies treated with both methods does not change during the follow-up period.
Of concern in the treatment of osteoporotic vertebral fractures is the high incidence of new fractures during follow-up. With vertebroplasty, 48% of the patients had new fractures, most of them in vertebral bodies adjacent to treated ones (4), and with kyphoplasty the refracture rate was 22%, again with most in adjacent vertebral bodies (5) . In another study with kyphoplasty treatment of compression fractures due to myeloma (3), there were no refractures.
There are two problems with osteoporotic vertebral fractures treated with vertebroplasty or kyphoplasty. One is predicting future fractures. In a study by MACHARA et al. (2) , it was shown that the use of intravenous contrast medium does not improve the possibility to foresee fractures. The other and more important problem is that there is no effective shortterm treatment to improve the quality of bone. There are, however, medication regimes that, in the long run, will help to strengthen the bone trabeculae and to improve the concentration of calcium in the skeleton. In the group of patients treated with kyphoplasty (5), antiosteoporotic medication was prescribed, but only two-thirds of the patients took the medication. In the vertebroplasty cohort there was no mention of postoperative medication. The lower rate of refractures in the kyphoplasty group may to some extent be due to the medication given.
In the myeloma group (3), patients were treated with radiotherapy and/or chemotherapy 2 to 4 weeks postinterventionally. This is probably where the greatest difference lies: in myeloma there is effective antitumor treatment that can be given immediately postoperatively, while there is limited treatment possibility with osteoporosis. This is probably the most challenging development in osteoporosis treatment. With vertebroplasty and kyphoplasty, the immediate pain due to compression fracture can be relieved, and the kyphosis deformity and vertebral height can be restored to some extent, but we need a method that can relatively quickly improve the general strength of the vertebrae and thus prevent new fractures. Until such medication is developed, we need to carefully follow up treated patients and be prepared to diagnose new fractures and treat them with interventional methods.
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